App-Based Insulin Calculators: Current and Future State
- 40 Downloads
Purpose of Review
To perform a comprehensive literature review and critical assessment of peer-reviewed manuscripts addressing the efficacy, safety, or usability of insulin calculator apps.
Managing diabetes with insulin can be complex, and literacy and numeracy skills pose barriers to manual insulin dose calculations. App-based insulin calculators are promising tools to help people with diabetes administer insulin safely and have potential to improve glycemic control. While a large number of apps which assist with insulin dosing are available, there is limited data evaluating their efficacy, safety, and usability. Recently, a need for regulatory oversight has been recognized, but few apps meet federal standards. Thus, choosing an appropriate app is challenging for both patients and providers. An electronic literature review was performed to identify insulin calculator apps with either evidence for efficacy, safety or usability published in peer-reviewed literature or with FDA/CE approval. Twenty apps were identified intended for use by patients with diabetes on insulin. Of these, nine included insulin calculators. Summaries of each app, including pros and cons, are provided.
Insulin-calculator apps have the potential to improve self-management of diabetes. While current literature demonstrates improvements in quality of life and glycemic control after use of these programs, larger trials are needed to collect outcome and safety data. Also, further human factor analysis is needed to assure these apps will be adopted appropriately by people with diabetes. App features including efficacy and safety data need to be easily available for consumer review and decision making. Higher standards need to be set for app developers to ensure safety and efficacy.
KeywordsSmartphone applications Insulin bolus calculators Type 1 diabetes Type 2 diabetes FDA
Compliance with Ethical Standards
Conflict of Interest
Leslie Eiland, Meghan McLarney, Thiyagarajan Thangavelu, and Andjela Drincic declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Centers for Disease Control and Prevention: Diabetes Public Health Resource. 2012. https://www.cdc.gov/diabetes/statistics/meduse/fig2.htm. Accessed 13 August 2018.
- 7.Sussman A, Taylor EJ, Patel M, Ward J, Alva S, Lawrence A, et al. Performance of a glucose meter with a built-in automated bolus calculator versus manual bolus calculation in insulin-using subjects. J Diabetes Sci Technol. 2012;6:339–44. https://doi.org/10.1177/193229681200600218.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.• Hirsch IB, Parkin CG. Unknown safety and efficacy of smartphone bolus calculator apps puts patients at risk for severe adverse outcomes. J Diabetes Sci Technol. 2016;10:977–80. https://doi.org/10.1177/1932296815626457. This article discusses the challenges that patients on MDI therapy face when manually calculating bolus insulin doses. While insulin calculator apps are a promising way to addresses these issues, there are also many concerns about the safety and efficacy of currently-available apps. CrossRefPubMedPubMedCentralGoogle Scholar
- 10.• Huckvale K, Adomaviciute S, Prieto JT, Leow MK, Car J. Smartphone apps for calculating insulin dose: a systematic assessment. BMC Med. 2015;13:106–015–314-7. https://doi.org/10.1186/s12916-015-0314-7. This article provides a thorough assessment of English-language rapid acting insulin dose calculators, and points out the many issues with safety and accuracy that HCPs need to be aware of prior to recommending an app to their patients. CrossRefGoogle Scholar
- 12.U.S. Food & Drug Administration: International Medical Device Regulators Forum (IMDRF). 2008. https://www.fda.gov/MedicalDevices/InternationalPrograms/IMDRF/default.htm. Accessed 13 August 2018.
- 14.Sun C, Malcolm JC, Wong B, Shorr R, Doyle MA. Improving glycemic control in adults and children with type 1 diabetes with the use of smartphone-based Mobile applications: a systematic review. Can J Diabetes. 2018.Google Scholar
- 16.• Veazie S, Winchell K, Gilbert J, Paynter R, Ivlev I, Eden KB, Nussbaum K, Weiskopf N, Guise JM, Helfand M. Rapid evidence review of mobile applications for self-management of diabetes. J Gen Intern Med. 2018; https://doi.org/10.1007/s11606-018-4410-1. This study provides a thorough review of apps currently available for people with Type 1 and Type 2 diabetes that have evidence available in the literature. CrossRefGoogle Scholar
- 17.Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. https://doi.org/10.1371/journal.pmed.1000100.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. Diabetes Care. 2013;36:3613–9. https://doi.org/10.2337/dc13-0251.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Mora P, Buskirk A, Lyden M, Parkin CG, Borsa L, Petersen B. Use of a novel, remotely connected diabetes management system is associated with increased treatment satisfaction, reduced diabetes distress, and improved glycemic control in individuals with insulin-treated diabetes: first results from the personal diabetes management study. Diabetes Technol Ther. 2017;19:715–22. https://doi.org/10.1089/dia.2017.0206.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Drion I, Pameijer LR, van Dijk PR, Groenier KH, Kleefstra N, Bilo HJ. The effects of a mobile phone application on quality of life in patients with type 1 diabetes mellitus: a randomized controlled trial. J Diabetes Sci Technol. 2015;9:1086–91. https://doi.org/10.1177/1932296815585871.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, et al. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 study). Diabetes Care. 2011;34:533–9. https://doi.org/10.2337/dc10-1259.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Rossi MC, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, et al. Diabetes Interactive Diary: a new telemedicine system enabling flexible diet and insulin therapy while improving quality of life: an open-label, international, multicenter, randomized study. Diabetes Care. 2010;33:109–15. https://doi.org/10.2337/dc09-1327.CrossRefPubMedGoogle Scholar
- 25.Rossi MC, Nicolucci A, Lucisano G, Pellegrini F, Di Bartolo P, Miselli V, et al. Impact of the “Diabetes Interactive Diary” telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes. Diabetes Technol Ther. 2013;15:670–9. https://doi.org/10.1089/dia.2013.0021.CrossRefPubMedGoogle Scholar
- 26.Garg SK, Shah VN, Akturk HK, Beatson C, Snell-Bergeon JK. Role of mobile technology to improve diabetes care in adults with type 1 diabetes: the Remote-T1D Study iBGStar((R)) in type 1 diabetes management. Diabetes Ther. 2017;8:811–9. https://doi.org/10.1007/s13300-017-0272-5.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Pfutzner A, Stratmann B, Funke K, Pohlmeier H, Rose L, Sieber J, et al. Real-world data collection regarding titration algorithms for insulin glargine in patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2016;10:1122–9. https://doi.org/10.1177/1932296816654714.CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm--2016 Executive Summary. Endocr Pract. 2016;22:84–113. https://doi.org/10.4158/EP151126.CS.CrossRefPubMedGoogle Scholar
- 33.Knight BA, McIntyre HD, Hickman IJ, Noud M. Qualitative assessment of user experiences of a novel smart phone application designed to support flexible intensive insulin therapy in type 1 diabetes. BMC Med Inform Decis Mak. 2016;16:119–016–0356-6. https://doi.org/10.1186/s12911-016-0356-6.CrossRefGoogle Scholar
- 37.Accueil | Diabeo®. 2018. https://www.diabeo.fr/. Accessed 14 August 2018.
- 38.DID Plus - Diabetes Interactive Diary - Meteda. 2018. http://www.meteda.it/en/product/did-diario-interattivo-del-diabete/. Accessed 14 August 2018.
- 40.Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med. 2006;23:736–42.CrossRefGoogle Scholar
- 41.Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755–62. https://doi.org/10.2337/dc14-0991.CrossRefPubMedGoogle Scholar
- 43.Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36:858–64. https://doi.org/10.2337/dc12-1668.CrossRefPubMedPubMedCentralGoogle Scholar
- 46.Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care. 2015;38:1008–15. https://doi.org/10.2337/dc15-0100.CrossRefPubMedGoogle Scholar
- 48.SNAPCARBS. 2018. https://diabnext.com/snapcarbs/. Accessed 14 August 2018.
- 50.Food and Drug Administration (FDA): Medical Devices - Cybersecurity. 2018. https://www.fda.gov/MedicalDevices/DigitalHealth/ucm373213.htm. Accessed 14 August 2018.
- 51.Rapid Calc: A small revolution in diabetes management. http://www.gilport.com/rapidcalc/index.html. Accessed 14 August 2018.
- 52.Boyle L, Grainger R, Hall RM, Krebs JD. Use of and beliefs about mobile phone apps for diabetes self-management: surveys of people in a hospital diabetes clinic and diabetes health professionals in New Zealand. JMIR Mhealth Uhealth. 2017;5:e85. https://doi.org/10.2196/mhealth.7263.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Jordan P, Thomas B, Weerdmeester B, McClelland I. Usability Evaluation In Industry. 1996.Google Scholar